Journal of Liver Cancer

Review Article

A concise review of updated global guidelines for the management of hepatocellular carcinoma: 2017-2024: Hyunjae Shin, Su Jong Yu; J Liver Cancer. 2025;25(1):19-30. Published online February 10, 2025; DOI: https://doi.org/10.17998/jlc.2025.02.03

32,789 Views
1,090 Downloads
18 Citations

Many guidelines for hepatocellular carcinoma (HCC) have been published and are regularly updated worldwide. HCC management involves a broad range of treatment options and requires multidisciplinary care, resulting in significant heterogeneity in management practices across international communities. To support standardized care for HCC, we systematically appraised 13 globally recognized guidelines and expert consensus statements, including five from Asia, four from Europe, and four from the United States. These guidelines share similarities but reveal notable discrepancies in surveillance strategies, treatment allocation, and other recommendations. Geographic differences in tumor biology (e.g., prevalence of viral hepatitis, alcohol-related liver disease, or metabolic dysfunction-associated steatotic liver disease) and disparities in available medical resources (e.g., organ availability, healthcare infrastructure, and treatment accessibility) complicate the creation of universally applicable guidelines. Previously, significant gaps existed between Asian and Western guidelines, particularly regarding treatment strategies. However, these differences have diminished over the years. Presently, variations are often more attributable to publication dates than to regional differences. Nonetheless, Asia-Pacific experts continue to diverge from the Barcelona Clinic Liver Cancer system, particularly with respect to surgical resection and locoregional therapies, which are viewed as overly conservative in Western guidelines. Advancements in systemic therapies have prompted ongoing updates to these guidelines. Given that each set of guidelines reflects distinct regional characteristics, strengths, and limitations, fostering collaboration and mutual complementarity is essential for addressing discrepancies and advancing global HCC care.

Citations

Citations to this article as recorded by

An Engineered Curcuma longa Starch Nanoparticles: A multi-functional Biomaterial for anti-oxidant, anticancer, Antibacterial and anti-biofilm Agent
Siva Sankar Sana, Ramakrishna Vadde, Chaitany Jayprakash Raorane, Pham Van Hung, Tae Hwan Oh
Journal of Polymers and the Environment.2026;[Epub] CrossRef
A novel link between tumor cell metabolism and patient prognosis: Editorial on “Molecular classification of hepatocellular carcinoma based on zoned metabolic feature and oncogenic signaling pathway”
Eun Ji Jang, Pil Soo Sung
Clinical and Molecular Hepatology.2026; 32(1): 420. CrossRef
Comparing Two Distal Radial Hemostatic Devices for Radial Artery Patency Post-TACE: A Randomized Trial
Cheng-Chun Lee, Jia-Min Wu, Fen-Ni Tsai, Pao-Chia Chiu, Yu-Chen Chen, Ya-Lan Liang, Jen-I. Hwang, Kuan-Chun Hsueh
CardioVascular and Interventional Radiology.2026;[Epub] CrossRef
Improved Detection of Small (<2 cm) Hepatocellular Carcinoma via Deep Learning-Based Synthetic CT Hepatic Arteriography: A Multi-Center External Validation Study
Jung Won Kwak, Sung Bum Cho, Ki Choon Sim, Jeong Woo Kim, In Young Choi, Yongwon Cho
Diagnostics.2026; 16(2): 343. CrossRef
Adjuvant cytokine-induced killer cell immunotherapy in hepatocellular carcinoma: real-world data and 9-year extended follow-up of a randomized controlled trial
Hyunjae Shin, Youngsu Park, Byeong Geun Song, Won-Mook Choi, Hyung Joon Han, Youngwoo Lee, Tae-Jin Song, Jong-Eun Yeon, Young-Suk Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Su Jong Yu, Yoon Jun Kim, Joon Hyeok Lee, Jung-Hwan Yoon, Jeong-Hoon Lee
Cancer Immunology, Immunotherapy.2026;[Epub] CrossRef
Exosomal microRNA‑448 suppresses the malignant behaviors of liver cancer cells by targeting RAB7A and inhibiting glycolysis
Yuankun Chen, Tiantian Zhu, Fang Chen, Mingyue Niu, Haifeng Wu, Qiuping Wu, Zheng Wang, Wenting Li
Oncology Letters.2026; 31(3): 1. CrossRef
Anticancer effects of Chlorella sorokiniana Shihira and R. W. Krauss extract via Bcl-2/Bax modulation and AMPK-α activation in hepatoma cells
Min Ho Han, Min Ho Kang, Youn Seon Hwang, Seung Won Nam, Chang Soo Lee, Jin Woo Kim
Journal of Functional Foods.2026; 137: 107172. CrossRef
Performance of the LI-RADS treatment response algorithm v2024: a systematic review and meta-analysis of response assessment accuracy and non-definitive categories
Mehrad Zare, Alisa Mohebbi, Ali Abdi, Afshin Mohammadi
Abdominal Radiology.2026;[Epub] CrossRef
Tailored proton beam therapy for hepatocellular carcinoma: Addressing unmet needs through a multidisciplinary approach
Jeong Ha Lee, Nalee Kim, Jeong Il Yu, Hee Chul Park, Sungkoo Cho, Byeong Geun Song, Myung Ji Goh, Wonseok Kang, Dong Hyun Sinn, Geum-Youn Gwak, Joon Hyeok Lee, Yong-Han Paik, Moon Seok Choi, Minsuk Kwon, Jung Yong Hong, Gyu-Seong Choi, Woo Kyoung Jeong, M
European Journal of Cancer.2026; 237: 116593. CrossRef
Radiofrequency Ablation Technology in Liver Malignancies: A Systematic Review of Economic Evaluations
Amirreza Taherkhani, Hoornaz Molana, Mahsa Taremi, Ghader Mohammadnezhad
Journal of Gastrointestinal Cancer.2025;[Epub] CrossRef
In Vitro and In Vivo Efficacy of the Essential Oil from the Leaves of Annona amazonica R.E. Fries (Annonaceae) Against Liver Cancer
Maria V. L. de Castro, Milena C. F. de Lima, Gabriela A. da C. Barbosa, Sabrine G. Carvalho, Amanda M. R. M. Coelho, Luciano de S. Santos, Valdenizia R. Silva, Rosane B. Dias, Milena B. P. Soares, Emmanoel V. Costa, Daniel P. Bezerra
Molecules.2025; 30(15): 3248. CrossRef
Spectrum of therapeutic options in hepatocellular carcinoma
Hyun Phil Shin, Moonhyung Lee, Jung Won Jeon
Journal of Exercise Rehabilitation.2025; 21(4): 190. CrossRef
Re-evaluating surgical strategies in Barcelona Clinic Liver Cancer-B hepatocellular carcinoma
Ioannis Liapis, Ioannis A Ziogas, Charalampos Theocharopoulos, Dimitrios P Moris, Trevor L Nydam, Ana L Gleisner, Richard D Schulick, Georgios Tsoulfas
World Journal of Hepatology.2025;[Epub] CrossRef
Predicting early progression to atezolizumab–bevacizumab in hepatocellular carcinoma: a clinical and imaging-based scoring system
Jae Hyon Park, Myung Ji Goh, Dong Hyun Sinn, Jaeseung Shin, Hyungjin Rhee
European Radiology.2025;[Epub] CrossRef
Unraveling the role of flotillin-1 in driving hepatocellular carcinoma progression through transcription factor E3-mediated Golgi stress response
Chiara Mazziotta, John Charles Rotondo
World Journal of Gastroenterology.2025;[Epub] CrossRef
The synergistic action of HDAC inhibitor with cisplatin impedes survival and proliferation of drug-tolerant persister in gastric and liver cancer cells
Anjali Singh, Abhiram Natu, Flevia Anthony, Hemalatha Muthu, Bharat Khade, Duane T. Smoot, Hassan Ashktorab, Sanjay Gupta
Clinical Epigenetics.2025;[Epub] CrossRef
Repurposing HIV-Protease Inhibitor Precursors as Anticancer Agents: The Synthetic Molecule RDD-142 Delays Cell Cycle Progression and Induces Autophagy in HepG2 Cells with Enhanced Efficacy via Liposomal Formulation
Fabiana Crispo, Antonio Vassallo, Immacolata Faraone, Alessandro Santarsiere, Lucia Chiummiento, Mara Martinelli, Nicoletta Cascelli, Xavier Fernàndez-Busquets, Rocchina Miglionico, Ilaria Nigro, Carla Caddeo, Maria Francesca Armentano
International Journal of Molecular Sciences.2025; 26(21): 10305. CrossRef
Angiography-Assisted Cone-Beam CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma: Single-Center Workflow and Early Outcomes
Jung Ui Hong, Soon Gu Cho, Kyu Hong Lee, Ji Hoon Noh, Ro Woon Lee
Diagnostics.2025; 15(22): 2898. CrossRef

Case Reports

Combined Transarterial Chemoembolization and External Beam Radiotherapy in a Patient with Recurrent Huge Hepatocellular Carcinoma after Hepatic Resection: Jesang Yu, Jinhong Jung, Sang Min Yoon; J Liver Cancer. 2020;20(1):90-97. Published online March 31, 2020; DOI: https://doi.org/10.17998/jlc.20.1.90

5,953 Views
88 Downloads

Abstract PDF: The optimal treatment strategy for unresectable huge hepatocellular carcinoma (HCC) is yet to be established. Non-surgical monotherapy demonstrated insufficient oncologic outcomes in previously reported studies. To improve the clinical outcomes of unresectable huge HCC, combined locoregional treatments can be considered in selected cases. Here, we report a case of 58-year-old male patient who was treated with combined transarterial chemoembolization (TACE) and external beam radiotherapy for recurrent HCC after a previous hepatic resection. After combined TACE and radiotherapy for the intrahepatic lesion, two metastases were diagnosed in the pelvic bones and lung; each lesion was successfully treated with salvage radiotherapy. During the long-term follow-up period (around 8 years 7 months after combined TACE and radiotherapy for the recurrent huge HCC), no definite viable tumors were observed in any of the treated liver, bone, and lung lesions.

Spontaneous Regression of Recurred Hepatocellular Carcinoma with Multiple Lung Metastases: Beom Yong Yoon, Heon Young Lee, Se Woong Hwang, Se Young Park, Hye Jin Kim, Hye Won Jang,, Byung Seok Lee; J Liver Cancer. 2015;15(1):46-51. Published online March 31, 2015; DOI: https://doi.org/10.17998/jlc.15.1.46

1,706 Views
10 Downloads

Abstract PDF: Hepatocellular carcinoma (HCC) is the most common form of liver malignancy. Spontaneous regression of HCC is extremely rare phenomenon and mechanism of regression remains obscure. 75-year-old woman previously diagnosed with hepatitis C virus-related liver cirrhosis was found to have single mass in liver with elevation of α-fetoprotein level to 10,320 ng/mL. Transarterial chemoembolization (TACE) was performed. 27 months after TACE recurred HCC with multiple lung nodules were confirmed. The patient refused any therapeutic modality. The patient underwent follow-up without any anti-cancer treatment. 8 months after recurrence follow up computed tomography scan revealed spontaneous regression of HCC and completely disappeared lung nodules. The patient is currently doing well and without any evidence of recurrence. The causes of spontaneous regression of HCC are not well understood. Proposed mechanisms are ischemic injury, biological factors, herbal medicine, immunological variations. Further studies are necessary to improve our understanding of this rare phenomenon.

First
Prev
Page of 1
Next
Last

Search